MEMBRANOUS LUPUS NEPHROPATHY

三种免疫抑制剂的疗效和毒性 治疗方案将在膜性狼疮患者中进行评估 在12个月的研究期间， 肾脏的详细检查 肾功能、肾小球选择透过性和肾活检 将在开始和结束时进行形态学检查， 治疗 系统性红斑狼疮患者， 肾病范围蛋白尿和活检证实膜性 肾病将用隔日泼尼松治疗， 随机接受：a）无额外治疗（对照 组），B）静脉冲击环磷酰胺高达1.0克每 平方米体表面积每隔一个月共6次 剂量，或c）口服环孢菌素A高达200 mg/m2 体表面积每天共11个月。 狼疮疾病 将监测活动、肾功能检查和药物毒性 仔细 分析将包括比较 肾小球功能和病理学的良好结果以及 作为各治疗组中出现的药物相关毒性， 12个月的学习结束。

The efficacy and toxicity of three immunosuppressive drug regimens will be evaluated in patients with membranous lupus nephropathy over a 12 month study period. Detailed tests of renal function, glomerular permselectivity and kidney biopsy morphology will be conducted at the beginning and end of treatment. Patients with systemic lupus erythematosus, nephrotic range proteinuria and biopsy documented membranous nephropathy will be treated with alternate day prednisone and will be randomized to receive: a) no additional therapy (control group), b) intravenous pulse cyclophosphamide up to 1.0 gram per square meter body surface area every other month for 6 total doses, or c) oral cyclosporin A up to 200 mg per square meter body surface area daily for a total of 11 months. Lupus disease activity, renal function tests and drug toxicities will be monitored closely. Analysis will include comparison of the number of favorable outcomes of glomerular function and pathology as well as drug-related toxicities appearing in each treatment group at the end of 12 months of study.